Press centre

Press release: Uppsala, November 23, 2020. A summary of the Interim report January - September 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .

Press release: Uppsala, November 18, 2020. Dicot has produced its second large-scale batch of the drug substance for Libiguin®. The production has improved significantly, which means that 2.5 times as much drug substance has been produced from the sa...

Uppsala, October 27, 2020. The agreement with Mangold Fondkommission to act as the liquidity provider for Dicot AB's share has been terminated. The assignment will end on October 29, 2020. The share has a good spread and the liquidity providing is no...

Press release: Uppsala, October 19, 2020. Dicot AB ("Dicot" or the "Company") announce the outcome regarding exercising of warrants of series TO1 2019 for the subscription of new shares. In total, 2,894,950 warrants were exercised, corresponding to a...

Today, October 13, is the last day of trading with the warrants of series TO1 2019. The subscription period for the warrants of series TO1 2019 will continue up until October 15, 2020. Each warrant entitles the owner to subscribe for one point eighty...

Press release: Uppsala, October 12, 2020. As previously reported, Dicot has conducted the first study in collaboration with Pelvipharm SAS with tests in a model for erectile function in normal rats. Satisfactory results showed that treatment with Dic...

Press release: Uppsala, October 6, 2020. Dicot AB, together with its partner in South Africa, Parceval Ltd, has initiated a partnership with the BioInnovation Africa (BIA) project of the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) t...

Press release: Uppsala, September 29, 2020. In accordance with what was communicated on July 8 the Board of Directors of Dicot (the "Company"), due to the rights issue of units that was carried out and heavily oversubscribed during the second quarter...

Uppsala, September 14, 2020. Dicot today announces the first results of the animal study conducted together with Pelvipharm.  The results show that Dicot's drug candidate Libiguin® had a significant and dose-dependent effect on erection compared to p...

Press release: Uppsala, August 27, 2020. A summary of the Interim report January - June 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .

Press release: Uppsala, July 17, 2020. Dicot AB (publ) ("Dicot" or the "Company") announces today, July 17, the following disclosure notice as a result of the Company's completed rights issue.

Press release: Uppsala, July 8 2020. Dicot AB (publ) ("Dicot") will, in accordance with the terms for the warrants 2019/2020, carry out a recalculation in accordance with the warrant terms as a result of the latest completed rights issue of units pub...

Press release: Uppsala, July 7, 2020. Dicot AB ("Dicot" or the "Company") has completed the rights issue of units amounting to SEK 21.8 million, which was disclosed on April 23, 2020 and resolved by the annual general meeting on May 26, 2020 (the "Ri...

Dicot AB (publ) ("Dicot" or the "Company") has conducted a rights issue of approximately SEK 21.8 million (the "Rights Issue"). The Rights Issue was subscribed with 326 percent. In total, 5,453,576 units were issued in the Rights Issue consisting of ...

Press release: Uppsala, June 24, 2020. The rights issue of SEK 21.8 million which was disclosed on April 23, 2020 and resolved by the annual general meeting on May 26, 2020 (the "Rights Issue")  in Dicot AB (publ) ("Dicot" or the "Company") has been ...

Uppsala, June 16, 2020. Dicot AB announces that the company has launched an English version of the website www.dicot.se, a step forward to reach the international market.

Press release: June 3, 2020. Dicot AB ("Dicot" or "the Company") has established an EU growth prospectus (the ''Prospectus'') related to the Company's rights issue, which was made public on April 23, 2020 and resolved by the annual general meeting on...

(Earlier today, December 11, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature). Jessica Roxhed joins Dicot as CFO, Julie Silber's role...

Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.

(The previous press release was sent out at 08:00 CET and has been updated to correct a spelling error. Nothing else differs from the previous press release.) November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nominat...